References
- Heath RJ, Rock CO. Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs. 2004;5:146–53.
- Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, et al.. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 2007;51:1580–1.
- Kaplan N, Yethon J, Albert M, Bardouniotis E, Thalakada R, Walsh N, et al.. In vitro characterization of API-1252, a novel inhibitor of bacterial fatty acid biosynthesis, against drug resistant staphylococci. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco, CA, USA. Poster F1-0754.
- Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, et al.. AFN-1252 — mode of action, in vitro activity and in vivo efficacy of a selective anti-staphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012;56(11):5865–74.
- Banevicius MA, Deryke CA, Kaplan N, Vaughan D, Nicolau DP. In vivo pharmacodynamic profiling of API-1252 against Staphylococcus aureus in a murine thigh model. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco, CA, USA. Poster F1-0759.
- Weis WJ, HafkinB, Kaplan N, Pulse M, Nguyen P, Renick P, et al.. Oral pharmacokinetics and effficacy of AFN-1252 in a murine septicaemia infection model with S. aureus. Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12–15; Boston, MA, USA. Poster F1-833.
- Kaplan N, Hafkin B. Tolerability, safety and pharmacokinetics of multiple oral doses of AFN-1252 in healthy subjects. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco, CA, USA. Poster F1-1349.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15. Wayne, PA: CLSI; 2005.
- Kaplan N, Flanner H, Hafkin B. Correlation of AFN-1252 phase 0 microdosing and phase I pharmacokinetics. F1-2006. Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12–15; San Francisco, CA, USA. Poster F1-2009.
- Harigaya Y, Bulitta JB, Forrest A, Sakouluas G, Lesse AJ, Mylotte JM, et al.. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother. 2009;53:3894–901.
- Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother. 2008;52:1533–7.
- Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26A. Wayne, PA: CLSI; 1999.
- Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother. 2007;60:568–9.
- Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, et al.. The MUR056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011;55:4692–7.
- Banevicius MA, Deryke CA, Kaplan N, Vaughan D, Nicolau DP. In vivo pharmacodynamic profiling of API-1252 against Staphylococcus aureus in a murine thigh model. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco, CA, USA. Poster F1-0759.